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Omega-3 polyunsaturated fatty acids (n-3 PUFA) consumption is associated with reduced cardiovascular disease risk. Increasing
evidence demonstrating a beneficial effect of n-3 PUFAon arterial wall properties is progressively emerging.We reviewed the recent
available evidence for the cardiovascular effects of n-3 PUFA focusing on structural and functional properties of the vascular wall.
In experimental studies and clinical trials n-3 PUFA have shown the ability to improve arterial hemodynamics by reducing arterial
stiffness, thus explaining some of its cardioprotective properties. Recent studies suggest beneficial effects of n-3 PUFAon endothelial
activation, which are likely to improve vascular function. Several molecular, cellular, and physiological pathways influenced by n-3
PUFA can affect arterial wall properties and therefore interfere with the atherosclerotic process. Although the relative weight of
different physiological and molecular mechanisms and the dose-response on arterial wall properties have yet to be determined,
n-3 PUFA have the potential to beneficially impact arterial wall remodeling and cardiovascular outcomes by targeting arterial wall
stiffening and endothelial dysfunction.
1. Introduction
Cardiovascular disease is the first cause of death in the
developed world. Its main feature is the extensive presence
of atherosclerosis, which is anticipated by morphologic
and functional changes involving vessel wall and vascular
endothelium. Impairment of functional properties of the
arteries is strictly related to the morphologic changes in
vessel structure and to the alteration inmechanical properties
[1, 2]. Endothelial dysfunction is characterized by impaired
endothelium-dependent vasodilation and “endothelial acti-
vation,” which is associated with a proinflammatory and pro-
coagulatory milieu that promotes development and progres-
sion of vascular disease [3, 4]. Cardiovascular risk factors are
closely linked to the development of endothelial dysfunction
and arterial wall stiffness, which are significant predictors
of cardiovascular risk and mortality [5, 6]. A synergistic
interplay exists among the anatomic structures of the vessel
wall, the vascular endothelium, endothelial-derived factors,
and circulating cytokines, and such interplay promotes the
development of overt atherosclerosis.
Omega-3 polyunsaturated fatty acids (n-3 PUFA) have
shown the potential to beneficially impact fundamental steps
involved in the development of preclinical atherosclerosis [7].
By targeting arterial stiffness and endothelial dysfunction,
administration of n-3 PUFAmay prevent atherosclerosis and
cardiovascular disease. A wide range of molecular and phys-
iological pathways are affected by n-3 PUFA administration
and are involved in the regulation of arterial stiffness and
endothelial dysfunction.
This review will focus on the complex nature of arterial
stiffness and endothelial dysfunction and on the translational
potential of n-3 PUFA for treating vascular remodeling.
2. Structural and Mechanical Properties of
the Arterial Wall
Arterial wall consists of a complex morphological orga-
nization, with multiple layers designed to maintain the
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fundamental properties of blood carrying and blood pressure
regulation. This structure is aimed at maintaining the elastic
properties of the arterial wall, which are important for
the physiological vascular function [8]. The distensibility of
arterial vessels determines the amplitude of pulse pressure
as well as the speed of the propagating pulse wave in the
arterial system. The loss of elastic properties leads to arterial
stiffness, a parameter that has been recognized in recent years
as an intermediate endpoint for cardiovascularmorbidity and
mortality, independently of conventional risk factors for car-
diovascular disease [9]. Arterial stiffening or arteriosclerosis,
which is caused by the loss of the medial arterial load bearing
components of the arterial wall, is pathologically distinct
from the obstructive condition of arteries or atherosclerosis,
usually defined as the deposition of lipids, white blood
cells, and calcium in the arterial wall [10], although these
two conditions are closely intertwined [11]. Arteriosclerosis
could directly promote cardiovascular disease, by increasing
pulsatile load on heart, reducing myocardial blood flow,
damaging small vessels in kidney or brain, and by promoting
atherogenesis through a reduction in shear stress rate. On
the other hand, the presence of atherosclerotic plaques could
mechanically alter the properties of the arterial wall.
The assessment of arterial stiffness has been increasingly
used in clinical setting, considering its good predictive value
for cardiovascular events. A large number of studies have
been addressed to understand the mechanisms and factors
influencing the development of arterial stiffness and to report
interventions able to influence arterial wall properties [9].
Reducing arterial stiffness may be useful to reduce incidence
of cardiovascular events and mortality; thus evidence-based
treatments would be clinically important, but currently a
specifically designed therapeutic strategy for this purpose
has not yet been defined. Dietary habits are well-known
determinants of the vascular changes occurring in the arterial
wall with age, and many studies have focused on the effects
of pharmacologic and nonpharmacologic interventions to
modulate arterial elastic properties [12].
3. Effects of n-3 PUFA on Atherogenesis
A large body of evidence demonstrates the substantial bene-
fits of n-3 PUFA in atherogenesis [13]. n-3 PUFA play several
important roles in cellular molecular mechanisms, tissue
metabolism and regulation, and act as pleiotropic agents
on the cardiovascular system [14]. The mechanisms through
which n-3 PUFA interfere with atherogenesis are therefore
multiple. Their effect on endothelial dysfunction, oxidative
stress, and inflammation, causing the onset of atherogenesis,
will be discussed in the next section. The antiatherogenic
effect of n-3 PUFA on serum lipid profile, with a reduction in
both triglycerides and very-low-density lipoproteins, is well
known and has recently been reviewed [15, 16]. However, it is
unclear as to how many of cardiovascular benefits are related
to n-3 PUFA lipid lowering effects and howmany of them are
due to lipid-independent effects.
Regarding the lipid deposition in the arterial layers,
which is associated with atherogenesis [17], in a mouse
animal model, n-3 PUFA were able to protect the arterial
wall by decreasing the LDL uptake and by directing lipid
deposition away from the aortic media, by decreasing the
lipoprotein lipase expression [18]. This antiatherogenic effect
is also associated with a reduction of macrophages and other
proinflammatorymarkers and is enhanced by an incremental
replacement of n-3 PUFA in the diet [19].
The proliferation of vascular smooth muscle cells and
their lipid accumulation are associatedwith early lesion in the
arterial wall and atherosclerosis promotion [20], highlighting
the role of these cells in the pathophysiology of vascular
remodeling [21]. An effect of n-3 PUFA on vascular smooth
muscle cells activation has been reported in several studies.
In culture cells, EPA and DHA were incorporated into
phospholipids and slow down the progression of cell cycle, by
inhibiting DNA synthesis and replication, thus suppressing
vascular smooth muscle cells proliferation [22]. A similar
inhibition in the proliferation of vascular smoothmuscle cells
was observed in human coronary arteries after consumption
of fish oil, with a regulation of adhesion molecules on these
cells [23].
A specific effect of n-3 PUFA on plaque stability has
also been reported, in preventing the rupturing of vulnerable
plaques, that leads to arterial thrombosis and obstruction.
This effect could explain the reduction in cardiovascular
endpoints observed in short-term trials conducted with
n-3 PUFA. In patients undergoing carotid endarterectomy,
atherosclerotic plaques revealed reduced macrophages infil-
tration andmore stablemorphology after n-3 PUFA adminis-
tration [24]. In amore recent study, in plaques of patients sup-
plemented with n-3 PUFA analyzed after carotid endarterec-
tomy, reduced inflammation and significantly lower levels of
mRNA for matrix metalloproteinases were observed [25].
The evaluation of intima-media thickness (IMT) has long
been used as a marker of atherosclerotic involvement of
arterial walls and as a surrogate endpoint of cardiovascular
disease [26]. Although several observational studies reported
an inverse association of n-3 PUFA administration, as diet
consumption or fish oil administration, a systemic review of
human intervention studies could not draw a firm conclusion
on the effects of n-3 PUFA administration on IMT [27]. Also
more recent trials were inconclusive: a positive effect on IMT
was observed in patients with type 2 diabetes [28], although,
in elderly men with hypercholesterolemia, a favorable effect
on IMT progression was not confirmed, whereas n-3 PUFA
imposed an improvement in arterial elasticity [29]. Recent
cross-sectional studies reported that DHA levels, but not
EPA, have an inverse association with IMT, suggesting that
DHA may have a more potent antiatherogenic effect than
EPA, independently of other risk factors [30].
4. Influence of n-3 PUFA on
Arterial Wall Stiffening
As above mentioned, the alteration of mechanical properties
of the arterial wall is strictly connected with atherosclerothic
involvement. An increased plaque burden and amodification
in the composition of arterial layers can hamper arterial elas-
tic behavior. Nevertheless, although sharing some common
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risk factors, these two processes should be considered sep-
arately. While effects of n-3 PUFA on atherogenesis, on
atherosclerotic plaques stability, and on arterial restenosis
have been previously extensively reviewed, we will focus on
n-3 PUFA effects on hemodynamic properties of the large
arteries. Arterial stiffness, while being firstly determined by
traditional risk factors for cardiovascular disease, can be
influenced by passive mechanisms that consider mechanical
and elastic properties of the vessels, and active mechanisms,
regulated by the cellular and molecular function of the
endothelium, the vascular smooth cells, and the extracellular
matrix [1]. Some of these mechanisms may be influenced by
n-3 PUFA intake.
Arterial blood pressure is considered the main deter-
minant of arterial stiffness [9]. A fundamental mechanical
property of the arteries is that the arterial wall becomes stiffer
when the distending pressure becomes higher. Hypertension
can also increase arterial stiffness chronically, by inducing
elastin fragmentation and arterial wall remodeling [31]. A
large body of studies demonstrated that n-3 PUFA are able
to reduce systemic blood pressure [32], and a recent meta-
analysis confirmed that a consumption of >2 g/d of EPA +
DHA can reduce systolic and diastolic blood pressure in
humans [33]. Thus, blood pressure, a main factor associated
with arterial stiffening, is influenced by n-3 PUFA intake,
explaining part of the beneficial effect of fatty acids on the
arterial wall.
Triglyceride levels are known to be affected by n-3
PUFA intake. A supplementation of 2-3 g/d of EPA + DHA
can reduce triglyceride levels by 25–30%, although a slight
increase of LDL levels was observed in some studies [34].
Lipid abnormalities are well-known determinants for the
development of atherosclerotic vessels disease and related
abnormalities, such the stiffening of large arteries. In large
cross-sectional studies [35] triglyceride levels were strongly
associated with arterial properties, although a specific benefit
in arterial stiffness levelswith therapies targeting triglycerides
has not been demonstrated yet.
Elevated heart rate has been shown to be associated
with an increased risk of cardiovascular events, and there is
evidence that the heart rate is independently associated with
the progression of arterial stiffness, both in animal models
and in humans [36]. n-3 PUFA supplementation is able to
reduce resting heart rate and recovery after exercise. Experi-
mental studies suggested that heart rate lowering could result
from direct effects on cardiac electrophysiology [37, 38].
Some studies also suggested that n-3 PUFA might improve
neurogenic autonomic function of cardiovascular system,
through a modulation of vagal and sympathetic balance [39],
and an independent association between aortic stiffness and
muscle sympathetic nerve activity has been reported [40].
The effect of n-3 PUFA on classical risk factors for
cardiovascular disease may explain the favorable effect on
arterial stiffness. Nevertheless other mechanisms, mediated
through biochemical cellular signaling and through neuro-
genic and neuroendocrine pathways, have been explored.The
association between endothelial dysfunction and increased
arterial stiffness has been demonstrated in vitro [41] and in
vivo, both in animals and in humans [42, 43]. Considering
the known effect of n-3 PUFA on endothelial function,
which is discussed later in this review, this could be a main
explanation of the reduction of arterial stiffness observed
in experimental condition of n-3 PUFA supplementation.
An enhancement in endothelial-dependent vasodilation of
the muscular arterioles leads to a decrease in arterial stiff-
ness because mechanical stresses are transferred to elastin
components of the wall and because there is a reduction
in reflected pulse waves [44]. A direct vasodilatory effect
and an inhibition of constrictor response of DHA have
been demonstrated in humans [45]. An interrelation of this
vasodilatory effect has been found with different endocrine
pathways, as the vascular constrictor response to angiotensin
[46] and norepinephrine [47] is attenuated by n-3 PUFA in
humans.
Therefore, the improvement in arterial properties shown
after n-3 PUFA supplementation is multifactorial and
involves both passive and active mechanisms of arterial
hemodynamics, mediated by multiple cellular and molec-
ular pathways and influenced by some major cardiovascu-
lar risk factors (hypertension, blood lipids, and autonomic
balance).
5. n-3 PUFA and Arterial Stiffness:
In Vivo Studies
Many studies have focused directly on the evaluation of
arterial stiffness after n-3 PUFA supplementation (Table 1).
Considering animal models, Sato et al. [48] found that
supplementation of EPA reduced aortic PWV in high-
cholesterol-diet-fed rabbits. Masson et al. [49] reported that
pulse pressure obtained from telemetry, an index of arterial
stiffness, was reduced by n-3 PUFA in fructose-fed rats,
a model of insulin-resistant state. Similarly, Engler et al.
[50] demonstrated that DHA supplementation reduced pulse
pressure and vascular wall thickness in spontaneously hyper-
tensive rats. More recently our group demonstrated that n-3
PUFA supplementation prevents arterial stiffening [51] and
other vascular changes, such as baroreflex sensitivity [52]
induced by ovariectomy, in a rat experimental model of
menopause.
A number of randomized and controlled clinical trials
have been conducted to explore the effects of n-3 PUFA
on various endpoints related to arterial stiffness. A well-
conducted meta-analysis by Pase et al. in 2011 [53], consid-
ering 10 intervention trials of n-3 PUFA supplementation,
reported that the 2 main outcomes examined (PWV and
systemic arterial compliance) were favorably affected by the
intervention, thus providing strong support to the use of n-3
PUFA as an evidence-based mean to reduce arterial stiffness.
The randomized clinical trials considered in this meta-
analysis consideredmainly high risk patients, with cardiovas-
cular risk factors ranging from dyslipidemia, hypertension,
and obesity to type 2 diabetes. More recent trials confirmed
this result with the validated endpoint of carotid-femoral
PWV, actually considered the gold standardmeasure for arte-
rial stiffness [9]. These studies, performed in special patient
population such as healthy smokers [54] and metabolic
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Table 1: Studies evaluating n-3 PUFA effects on arterial stiffness.
(a) Animal studies
First author Year Dose Sample Duration(w)
Study
design
Outcome
measure Results
Sato [48] 1993 300mg/kg/dayEPA
High-
cholesterol-diet-
fed
rabbits
12 AES-PG cf-PWV Prevent increase incf-PWV
Engler [50] 2003 DHA-enriched oil
Spontaneous
hypertensive
rats
6 AES-PG Wallthickness, PP
Reduce wall
thickness and PP
Masson [49] 2008 diet enriched w.16 g/kg n-3 PUFA
Fructose-fed
rats 10 AES-PC PP
Prevent increase in
PP
Losurdo [51] 2014 0.65 g/kg/d versusplacebo by gavage
Ovariectomized
rats 8 AES-PC cf-PWV
Prevent increase in
cf-PWV
(b) Human studies
First author Year Dose Sample Duration(w) Number
Study
design
Outcome
measure Results
McVeigh
[110] 1994
1800mg EPA + 1200
mg DHA/d versus
placebo (olive oil)
Type 2
diabetes 6 20 RCT-PC Total AC
Increase in total
AC
Nestel [111] 2002
3000mg EPA/d
versus 3000 mg
DHA/d versus
placebo (olive oil)
Dyslipidemic 7 38 RCT-PC Total AC
Increase 36% with
EPA, 27% with
DHA
Tomiyama
[62] 2011
1800mg EPA/d versus
control (diet therapy) Dyslipidemic 52 84 RCT-PG ba-PWV
Reduction of
ba-PWV
Hjerkinn [29] 2006 2400mg n-3 PUFAversus control diet Dyslipidemic 156 563 RCT-PG cr-PWV
Decrease in
cr-PWV 4%
Hill [112] 2007
1560mg DHA +
360mg EPA/d versus
placebo (6 g
sunflower oil/d)
Overweight,
hypertensive,
dyslipidemic
6 to 12 38 RCT-PC Small and largeAC
Increase in small
AC 26%.
Mita [28] 2007 1800mg EPA/d versuscontrol (no EPA)
Type 2
diabetes 6 64 RCT-PG ba-PWV
Reduction of
ba-PWV
Wang [113] 2008
540mg EPA + 360mg
DHA versus placebo
capsules
Overweight,
hypertensive 8 52 RCT-PC
Small and large
AC
Increase in large
AC 21%
Satoh [114] 2009
1800mg EPA/d + diet
versus control (diet
only)
Metabolic
syndrome 12 92 RCT-PG ca-PWV
Reduction of
ca-PWV 6%
Ayer [115] 2009
32mg EPA/d + 135 mg
DHA/d + canola oil
versus control diet
Healthy
children 260 616 RCT-PG
Carotid artery
distensibility,
cb-PWV, Aix
No difference
Sjoberg [116] 2010
1560DHA + 360mg
EPA/d versus placebo
(sunola oil)
Overweight 12 67 RCT-PC Small and largeAC
Increase in large
AC 14%
Dangardt
[60] 2010
1200mg n-3 PUFA
versus placebo
Obese
adolescents 12 25 RCT-PC cf-PWV No difference
Sanders [58] 2011 1800mg n-3 PUFAversus placebo
Healthy
subjects 52 312 RCT-PC cf-PWV
Decrease in
cf-PWV
Haiden [57] 2012 1800mg n-3 PUFAversus placebo
Hypertensive,
dyslipidemic 52 19 CT
ba-PWV, aortic
strain rate
Decrease in
ba-PWV 1%, strain
rate 17%
Siasos [54] 2013 2000mg n-3 PUFAversus placebo
Healthy
smokers 12 20 RCT-PC cf-PWV
Decrease in
cf-PWV 6%
Root [59] 2013 1700mg n-3 PUFAversus placebo
Overweight
young 4 30 RCT-PC cf-PWV No difference
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(b) Continued.
First author Year Dose Sample Duration(w) Number
Study
design
Outcome
measure Results
Wong [56] 2013 4000mg n-3 PUFA +diet versus diet alone Obese 12 13 RCT-PC
Small and large
AC
Increase in large
AC 20%, small AC
22%
Tousoulis
[55] 2014
2000mg n-3 PUFA
versus placebo
Metabolic
syndrome 12 29 RCT-PC cf-PWV
Decrease in
cf-PWV 5%
n-3 PUFA, omega-3 polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PWV, pulse wave velocity; cf, carotid-femoral;
ba, brachial-ankle; cr, carotid-radial; PP, pulse pressure; AC, arterial compliance; AES, animal experimental study; RCT, randomized clinical trial; CT,
clinical trial; PG, parallel groups; PC, placebo controlled; d, day; w, week.
syndrome patients [55], confirmed a reduction in arterial
stiffness. A large study conducted evaluating carotid-radial
PWV in elderly men with hypercholesterolemia [29] and
systemic arterial compliance in obese patients on a weight
loss diet [56] confirmed a favorable effect in arterial stiffness.
Considering innovative measurement methods of arterial
stiffness, a small open-label study observed an improvement
in regional aortic stiffness assessed by strain rate, using
tissue Doppler imaging [57].Three randomized clinical trials
conducted with small doses of n-3 PUFA (<1.8 g/d) on
healthy patients [58] and on young healthy patients with
metabolic syndrome [59] or obesity [60] did not find any
significant effect on arterial stiffness. In a trial evaluating
patients with cardiovascular risk factors a fish oil diet was
ineffective in reducing brachial-ankle pulse wave velocity,
while the subsequent administration of pure EPA in the
same population significantly reduced the arterial stiffness
[61]. Considering cross-sectional studies, in general Japanese
population, there was no relationship between serum omega-
3 levels and arterial stiffness, evaluated as brachial-ankle
PWV [62], while in a sample of 299 Korean men a regression
analysis found a significant inverse association with total n-3
PUFA and carotid-femoral PWV [63].
Despite the few negative results in randomized clinical
trials, current evidences generally agree that n-3 PUFA are
effective in reducing arterial stiffness in humans. We can
speculate that the negative results in these trials [58–60] are
due to the small dose of active treatment or to the fact that
in these trials a population with a low risk for cardiovascular
disease was considered (young patients, healthy volunteers).
The preferred use of n-3 PUFA only in high risk patients or
in secondary prevention is supported by current guidelines
and could be applied also for n-3 PUFAadministration for the
purpose of reducing arterial stiffness, although well-designed
clinical trials considering high and low risk population are
needed to support this evidence.
As arterial stiffness is a strong risk factor for cardiovas-
cular disease, n-3 PUFA should be considered, among the
wide range of cardiovascular drugs, as a safe and evidence-
based choice to positively affect the mechanical properties
of arterial wall. Which dose is the best for this outcome
and which group of patients should be treated constitute an
important area of future research.
6. Regulation of Endothelial Function and
Endothelial Dysfunction
Classically the term “endothelial dysfunction” strictly refers
to reduced endothelium-dependent vasodilation, which is
notably associated with impaired bioavailability of the main
endothelium-derived relaxing factor, nitric oxide (NO). In
addition to promoting vasodilation, NO is a powerful
antiatherosclerotic agent, since it reduces leukocyte adhesion,
platelet aggregation, and smooth muscle cell proliferation
[64]. In the endothelium NO is produced by the enzyme
endothelial nitric oxide synthase (eNOS). Reduced nitric
oxide bioavailability can be the result of either decreased
production or increased scavenging. Several mechanisms,
including downregulation of eNOS expression, posttrans-
lational modifications of eNOS, inhibition of the enzyme
catalytic activity, enzyme uncoupling, and circulating eNOS
inhibitors result in decreased NO release and endothelial
dysfunction [65, 66].
On the other hand, a number of studies have shown that
reactive oxygen species (ROS), which are increased in many
conditions associated with enhanced oxidative stress, deter-
mine endothelial dysfunction by quenching NO, reducing its
bioavailability and leading to the formation of the highly toxic
peroxynitrite [66, 67].
Perturbations of NO bioavailability are usually associated
with signs of vascular inflammation and of a prothrombotic
and procoagulable state [68]. Therefore, in a comprehensive
sense, the term endothelial dysfunction encompasses a wide
range of alterations of endothelial function preluding overt
atherosclerosis.
Endothelial dysfunction is typically detected in condi-
tions associated with vascular disease, such as hypertension,
smoking, diabetes mellitus, hypercholesterolemia, and aging
[69]. Clinically, endothelial dysfunction can be noninvasively
assessed by measuring flow-mediated dilation (FMD), at
the level of the brachial artery or of the coronary bed.
This parameter allows determining the capability of the
vessel to dilate in response to various stimuli (hyperemia
following sphygmomanometer cuff inflation or infusion of
muscarinic receptor agonists) [4, 70]. Importantly, several
studies have demonstrated the prognostic value of endothe-
lial dysfunction in terms of future cardiovascular events in
both populations at low and high cardiovascular risk, its
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Figure 1: n-3 PUFA effects on vascular structure and function.
predictive value being not inferior to validated surrogate
markers of vascular function [4, 71–73].Therefore endothelial
dysfunction can be considered an early marker of increased
cardiovascular risk in patients with or without a previous
history of cardiovascular disease.
7. Influence of n-3 PUFA on
Endothelial Function
The mechanism by which n-3 PUFA influence endothelial
function is mediated by their incorporation into biolog-
ical membrane phospholipids; this allows modulation of
membrane composition and fluidity. The importance of
endothelial cell membrane composition has been docu-
mented by several studies (Table 2). The reason lies in the
fact that endothelial cell membrane houses caveolae and
lipid rafts where several receptors and signaling molecules
crucial for cell function are concentrated [74]. Caveolae-
associated receptor-mediated cellular signal transduction
includes important pathways such as the nitric-oxide cGMP
pathway, the NADPH oxidase and TNF-𝛼 –NF𝜅B induced
cyclooxygenase-2 (COX-2) and prostaglandin E
2
(PGE
2
)
activation pathway [75, 76]. By modulating the composition
of caveolae, as described for other classes of lipids [77]
n-3 PUFA may exert their beneficial effects, which include
increased NO production and reduced production proin-
flammatory mediators.
Molecular evidence of enhanced eNOS activity/expres-
sion following administration of n-3 PUFA derives from
experimental studies in endothelial cells in culture or in
animals. Wu et al. [78] showed that in bovine aortic endothe-
lial cells and in eNOS knock-out mice EPA induces NO
production by stimulating AMP-activated protein kinase
(AMPK) induced endothelial nitric oxide synthase (eNOS)
activation. Similarly, Omura et al. demonstrated that EPA
stimulates eNOS activation in endothelial cells by inducing its
dissociation from the inhibitory scaffolding protein caveolin
[79]. Likewise, Stebbins et al. reported that DHA promotes
eNOS activity by increasing the interaction between eNOS
andHSP-90, which activates PKB/AKt pathway finally result-
ing in eNOS phosphorylation and activation [80]. Finally, n-3
PUFA can enhance eNOS activity by reducing the circulating
levels of asymmetric dimethylarginine (ADMA), an endoge-
nous inhibitor of eNOS, which is increased in conditions as
hypertension, renal failure, and aging [81].
Another mechanism by which n-3 PUFA increase NO
production is by directly stimulating eNOS gene and pro-
tein expression. Improved vasodilation as a result of n-3
PUFA induced upregulation of eNOS gene/protein expres-
sion has been documented in a wide series of reports con-
sidering physiological and disease animal models including
menopause, atherosclerosis, and diabetes mellitus by our and
other groups [82–88]. Taken together these data indicate a
strong potential of n-3 PUFA to potentiate NO availability
by enhancing its production via different molecular mecha-
nisms.
In addition to increasing NO production, n-3 PUFA
decrease oxidative stress.This effect is controversial, since the
prooxidant activity of long-chain n-3 PUFA especially at high
doses has long been debated [89]. However experimental
studies conducted so far in cell culture or in vascular beds of
experimental animals have shown that relatively large doses
of n-3 PUFA improve endothelial function by attenuating
ROS production as a result of a direct modulatory effect
on the sources of ROS formation, including the enzymes
NADPH oxidase and iNOS, finally resulting in reduced
peroxynitrite formation [82, 83]. In retinal endothelial cells
in culture exposed to high glucose ALA directly reduces
ROS information and increased superoxide dismutase (SOD)
activity [90, 91]. A potentiation of endogenous antioxidant
enzyme concentrations in plasma as a direct effect of n-3
PUFA oral administration has also been reported also by
other reports [92].
Among the contributors to endothelial dysfunction, n-3
PUFA have shown the potential to attenuate cellular and
systemic inflammation. In endothelial cells in vitro n-
3 PUFA attenuate NF-𝜅B activation, resulting in reduced
VCAM-1 expression [90]. Additionally, n-3 PUFA exert
systemic anti-inflammatory effects by raising the plasma
levels of adiponectin [93] and suppressing the production
of interleukin 6, interleukin 1𝛽, soluble E selectin, and
CRP [94]. These effects are dose-dependent, as relatively
high doses of n-3 PUFA are required to achieve the anti-
inflammatory effect and this cannot exclude the fact that
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Table 2: Studies evaluating n-3 PUFA effects on endothelial function.
(a) Animal studies
First author Year Dose Sample Duration(w)
Study
design
Outcome
measure Results
Nyby [84] 2005
Diet enriched with
60% fructose and
4.4% n-3 PUFA
versus diet with
60% fructose or
control diet
Hyperinsulinemic
rats 8 AES-PG
EDD,
oxidative
stress
Improve EDD and
oxidative stress
Matsumoto [88] 2009
300mg/kg/day
EPA versus control
diet
Diabetic rats 4 AES-PC EDD Improve EDD
Zhang [83] 2013
Diet enriched with
ALA
500mg/kg/day
versus control diet
Type 2 diabetic
rats 5 AES-PC
EDD,
oxidative
stress
Improve EDD and
oxidative stress
Gortan
Cappellari [82] 2013
800mg/kg/day by
gavage versus
control diet
Ovariectomized
rats 8 AES-PC
EDD,
oxidative
stress
Improve EDD and
oxidative stress
(b) Human studies
First author Year Dose Sample Duration(w) Number
Study
design
Outcome
measure Results
Woodman
[117] 2003
3800mg EPA or
3700mg DHA versus
olive oil
Hypertensive type 2
patients 6 30 RCT-PG EDD, EID
Unchanged EDD
and EID
Engler [118] 2004 1200mg n-3 PUFAversus control diet
Hypercholesterolemic
children 10 20 RCT-PC
EDD,
oxidative
stress,
inflammation
Improved EDD,
unchanged
oxidative stress and
inflammation
Ros [119] 2004
1100–1700mg n-3
PUFA versus
Mediterranean diet
Hypercholesterolemic
patients 4 20 RCT-PG
EDD,
oxidative
stress and
CRP
Improved EDD,
unchanged
oxidative stress and
inflammation
Keogh [120] 2005
4700mgmg n-3
PUFA versus
isocaloric high
carbohydrate,
saturated or
monounsaturated fat
enriched-diet
Healthy subjects 4 40 RCT-PG EDD, CRP,inflammation
Improved EDD in
all groups except in
saturated fat
enriched diet
Prabodh
Shah [121] 2007
500mg n-3 PUFA
versus placebo Healthy subjects 2 26 RCT-PC EDD, EID
Improved EDD
and EID
Wright [122] 2008
3000mg n-3 PUFA
versus standard
therapy
Systemic lupus
erythematosus
patients
24 56 RCT-PG
EDD,
oxidative
stress
Improved EDD
and oxidative stress
Schiano [123] 2008 1700–2000mg versusstandard therapy
Intermittent
claudication patients 13 32 RCT-PG
EDD,
inflammation
Improved EDD,
inflammation
unchanged
Mindrescu
[124] 2008
4500mg n-3 PUFA +
rosuvastatin 10 g
versus rosuvastatin
10 g
Dyslipidemic patients 4 30 RCT-PG EDD, EID Improved EDDand EID
Rizza [125] 2009 1700–2000mg n-3PUFA versus placebo
Offspring of type 2
diabetic subjects 12 50 RCT-PC
EDD,
inflammation
Improved EDD
and inflammation
Wong [99] 2010
4000mg n-3 PUFA
versus control
(olive oil)
Type 2 diabetes
mellitus 12 97 RCT-PG
EDD, CRP,
renal
function
Improved renal
function; no effect
on EDD or CRP
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(b) Continued.
First author Year Dose Sample Duration(w) Number
Study
design
Outcome
measure Results
Stirban [100] 2010 2000mg versuscontrol (olive oil)
Type 2 diabetes
mellitus 6 34 RCT-PC
Postprandial
EDD
Improved
postprandial EDD
Sanders [58] 2011
450–900 or 1800mg
n-3 PUFA vresus
placebo (refined oil)
Healthy subjects 51 310 RCT-PC EDD Unchanged EDDand EID
Skulas-Ray
[101] 2011
850 or 3400mg versus
placebo
Moderate
hypertriglyceridemia 8 26 RTC-PC
EDD, IL-6,
CRP
No effect on EDD,
IL-6, or CRP
Moertl [103] 2011 1000 or 4000mg n-3PUFA versus placebo CHF 12 43 RCT-PC
LVEF, EDD,
IL-6
Improved LVEF,
EDD, and IL-6
Haberka
[104] 2011
1000mg n-3 PUFA
versus control
(standard diet and
therapy)
Previous AMI 12 40 RCT-PG EDD, EID Improved EDD;EID unchanged
Din [105] 2013 2000mg n-3 PUFAversus placebo Cigarette smokers 6 20 RCT-PC
EDD,
P-selectin,
CD40L
Improved EDD
and P selectin;
CD40L unchanged
Din [108] 2013 2000mg n-3 PUFAversus placebo Previous AMI 6 20 RCT-PC
EDD,
P-selectin,
CD40L
No effect
n-3 PUFA, omega-3 polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; EDD, endothelium dependent dilation;
EID: endothelium independent dilation; AMI: acute myocardial infarction; CHF: chronic heart failure; LVEF: left ventricular ejection fraction; IL-
6: interleukin-6; CRP: C reactive protein; AES, animal experimental study; RCT, randomized clinical trial; CT, clinical trial; PG, parallel groups; PC,
placebo controlled; d, day; w, week.
indirectly also the triglyceride-lowering effect contributes
to improved endothelial function often observed in these
conditions.
8. n-3 PUFA and Endothelial Dysfunction:
In Vivo Human Studies
n-3 PUFA show the potential to improve endothelial dysfunc-
tion by activating NO production via different mechanisms
and by reducing vascular oxidative stress and inflammation
(Figure 1). Many studies have evaluated the effect of n-
3 PUFA on human endothelial function and the results
have been reported by two recent meta-analyses [95, 96],
whose conclusions are not completely concordant. For review
reasons, we will focus on studies published during the last 5
years. One issue that needs to be considered when evaluating
the effect of n-3 PUFA supplementation on endothelial
function is the poverty of data on n-3 PUFA basal enrichment
in the patient population under consideration.The amount of
n-3 PUFA in biological membranes can be directly extrapo-
lated bymeasuring the omega-3 index in red blood cell mem-
branes [97, 98] or by determining plasma concentrations of
EPA + DHA which have shown a good correlation with their
membrane levels [89]. This point is crucial as conditions
characterized by n-3 PUFA depletion may mostly benefit
from their supplementation. In a recent study conducted
in an experimental model of menopause, deficiency of n-3
PUFA demonstrated by low omega-3 index was associated
with endothelial dysfunction and increased oxidative stress,
which were reversed by efficient n-3 PUFA supplementation,
resulting in normalization of omega-3 index [82].Having said
this, clinical trials on the effects of n-3 PUFA on endothelial
function are significantly heterogeneous in
(i) number of included participants;
(ii) inclusion criteria: age of participants, healthy or
disease state, have been studied;
(iii) markers of endothelial function: in addition to flow-
mediated dilation, at least 7 different classes of surro-
gate markers have been tested in the last 5 years. The
most frequent categories tested, according to their
different pathophysiological roles, are proinflamma-
tory and anti-inflammatory cytokines, endothelial
progenitor cells, markers of platelet activation, of
fibrinolysis, of thrombosis, and of coagulation, and
markers of oxidative stress [98–102];
(iv) dose and duration of treatment: doses ranging from
0.45 up to 4 grams have been tested as well as
treatments ranging from 4 to 52 weeks [58, 103, 104];
(v) forms of n-3 PUFA: EPA, DHA, or ALA has been
administered alone or in combination;
(vi) concomitant therapy: most of the studies on dis-
ease states do not provide accurate information on
concomitant therapy, particularly on drugs known
to improve endothelial function such as statins and
ACE inhibitors/angiotensin receptor blockers. The
presence of a robust concomitant therapy might
improve endothelial function independently of n-3
PUFA (especially at low doses) in high risk patients.
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So far, most studies have cautiously suggested that supple-
mentation with n-3 PUFA might improve endothelial func-
tion. However, whether the amplitude of this effect depends
on healthy or disease state or on the administered dose
or whether the n-3 PUFA composition of supplementation
differentially affects the outcome is currently unclear. In
smokers, where the bias of concomitant therapies is not an
issue, two recent studies have shown that n-3 PUFA supple-
mentation for six and twelve weeks, respectively, improves
endothelial function [54, 105]. In patients with moderate car-
diovascular risk Seely et al. performed a meta-analysis where
again quality and power of the available studies precluded any
definite conclusion [106]. However, low-strength evidence
seemed to suggest a benefit of n-3 PUFA in endothelial
dysfunction. Similar results have been reported in high risk
patients with previous myocardial infarction [104] although
a recent comprehensive meta-analysis and a recent study in a
similar population do not confirm these findings [107, 108].
When considering moderate/high risk patients assuming
polytherapy, the issue of cost/benefit in terms of clinical effi-
ciency and potential harms is important. Therefore, stronger
evidence is needed before large scale prescription of n-3
PUFA in this population.
9. Endothelial-Independent Vasodilation
and n-3 PUFA
Technically, flow-mediated dilation is the result of both
endothelial-derived vasodilation (which is mainly NO-
dependent) and endothelial-independent vasorelaxation.The
latter depends on the ability of smooth muscle cells to
respond to nitric oxide and therefore measures the integrity
of arterial media. The hypotensive effect of n-3 PUFA can
partly be explained by this mechanism. Therefore, when
measuring FMD in vivo in humans, it is difficult to dissect
the relative contribution of endothelium and smooth muscle
cells unless a selective agonist is administered (muscarinic
receptor agonist for EDD and NO donor for EID). A recent
study addressed the physiologicmechanisms of EPA-induced
relaxation in pulmonary arteries from an animal model [109]
and showed that in these conditions the contribution of
endothelium-derived NO release to vasodilation is promi-
nent, while that mediated by endothelium-independent
mechanisms is negligible.
These findings are in line with data from human studies,
showing that when controlled trials assessing EID are con-
sidered, no significant effect of n-3 PUFA on EID is observed
[96].
10. Conclusive Remarks
By targeting both arterial wall stiffness and endothelial dys-
function n-3 PUFA have the potential to beneficially impact
arterial wall remodeling and cardiovascular outcomes. Their
pleiotropic effects on systemic inflammation, modulation
of lipid profile, and platelet aggregation contribute to the
reduction of cardiovascular risk. Although dissecting the
specific contribution of structural arterial remodeling to
overall cardiovascular risk is difficult from experimental
studies conducted in high risk populations, current results are
encouraging. From here comes the need for large scale trials,
advocated by most of the available literature. This process is
likely to involve selection of homogenous patient populations
in terms of target disease, endpoints, and modality of treat-
ment.
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